Crossref

1. Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China

- Jian Sun

- Huiguo Ding

- Guofeng Chen

- Guiqiang Wang

- Lai Wei

- Jiming Zhang

- Qing Xie

- Mobin Wan

- Hong Tang

- Shijun Chen

- Zhiliang Gao

- Yuming Wang

- Dazhi Zhang

- Wenxiang Huang

- Jifang Sheng

- Qin Ning

- Dongliang Yang

- Jian Lu

- Chen Pan

- Yuxiu Yang

- Jue Wang

- Chuanzhen Sun

- Qixin Wang

- Jinlin Hou

2. Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs

- Jing Huang

- Ka Zhang

- Wenli Chen

- Jinyao Liao

- Xiaodan Luo

- Ren Chen

3. Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy

- Meng-Lan Wang

- Juan Liao

- Bing Wei

- Dong-Mei Zhang

- Ming He

- Ming-Chuan Tao

- En-Qiang Chen

- Hong Tang